I think Leo may have simply underestimated the length of time it takes to reach trial milestones. It just always takes longer than even the most seasoned clinical researcher expects. CEO's regularly end up in a no-win re pr's. They try to time things, and they get delays. Then people get frustrated for the CEO being wrong in guesstimates - understandably so. The only reason I think the p21 samples accumulated so far might soon be quantified and released is because of Leo's asco statement saying DF wanted more samples before running it. They may have minimum batch needed for quantification - I don't know the parameters for such a test run.

I thought about the negative possibility too. But when study is published - lab data including run time will be available - so I do not think results were there and unreported. This would reflect too poorly on the company. I do think we may still be too early to see positive results though.